Skip to main content
SpringerLink
Log in

Potential Role of P-Glycoprotein in Affecting Hepatic Metabolism of Drugs

  • Commentary
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCES

  1. R. B. Kim, C. Wandel, B. Leake, M. Cvetkovic, M. F. Fromm, P. J. Dempsey, M. M. Roden, F. Belas, A. K. Chaudhary, D. M. Roden, A. J. Wood, and G. R. Wilkinson. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm. Res. 16:408–414 (1999).

    Google Scholar 

  2. E. G. Schuetz and A. H. Schinkel. Drug disposition as determined by the interplay between drug-transporting and drug-metabolizing systems. J. Biochem. Mol. Toxicol. 13:219–22 (1999).

    Google Scholar 

  3. K. Yokogawa, M. Takahashi, I. Tamai, H. Konishi, M. Nomura, S. Moritani, K. Miyamoto, and A. Tsuji. P-glycoprotein-dependent disposition kinetics of tacrolimus: Studies in mdr1a knockout mice. Pharm. Res. 16:1213–1218 (1999).

    Google Scholar 

  4. L. Z. Benet, C. Y. Wu, M. F. Hebert, and V. J. Wacher. Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery. J. Controlled Rel. 39:139–143 (1996).

    Google Scholar 

  5. E. G. Schuetz, A. H. Schinkel, M. V. Relling, and J. D. Schuetz. P-glycoprotein: A major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc. Natl. Acad. Sci. U.S.A. 93:4001–4005 (1996).

    Google Scholar 

  6. E. G. Schuetz, D. R. Umbenhauer, K. Yasuda, C. Brimer, L. Nguyen, M. V. Relling, J. D. Schuetz, and A. H. Schinkel. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes. Mol. Pharmacol. 57:188–197 (2000).

    Google Scholar 

  7. W. L. Chiou, S. M. Chung, and T. C. Wu. Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice. Pharm. Res. 17:205–208 (2000).

    Google Scholar 

  8. J. van Asperen, A. H. Schinkel. J. H. Beijen, W. J. Nooijen, P. Borst, and O. van Tellingen. Altered pharmacokinetics of vinblastine in mdr1a P-glycoprotein-deficient mice. J. Natl. Cancer Inst. 88:994–999 (1996).

    Google Scholar 

  9. A. Sparreboom, J. van Asperen, U. Mayer, A. H. Schinkel, J. W. Smit, D. K. Meijer, P. Borst, W. J. Nooijen, J. H. Beijnen, and O. van Tellingen. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. U.S.A. 94:2031–2035 (1997).

    Google Scholar 

  10. E. G. Schuetz, K. Yasuda, K. Arimori, and J. D. Schuetz. Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a) pyrene. Arch. Biochem. Biophys. 350:340–347 (1998).

    Google Scholar 

  11. A. H. Schinkel, E. Wagenaar, L. van Deemter, C. A. A. M. Mol, and P. Borst. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96:1698–1705 (1995).

    Google Scholar 

  12. M. F. Fromm, R. B. Kim, C. M. Stein, G. R. Wilkinson, and D. M. Roden. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 99:552–557 (1999).

    Google Scholar 

  13. P. J. Murrhy, T. L. Williams, R. E. McMahon, and F. J. Marshall. Metabolism of propionyl erythromycin lauryl sulfate. I. Fate of the propionyl erythromycin moiety in the rat. Drug Metab. Dispos. 3:155–163 (1975).

    Google Scholar 

  14. R. B. Kim, M. F. Fromm, C. Wandel, B. Leake, A. J. J. Wood, D. M. Roden, and G. R. Wilkinson. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-I protease inhibitors. J. Clin. Invest. 101:289–294 (1998).

    Google Scholar 

  15. G. W. Wilkinson and D. G. Shand. Commentary: A physiological approach to hepatic drug clearance. Clin. Pharmacol. Ther. 18:377–390 (1975).

    Google Scholar 

  16. J. van Asperen, O. van Tellingen, and J. H. Beijnen. The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. Drug Metab. Dispos. 28:264–267 (2000).

    Google Scholar 

  17. P. B. Watkins. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv. Drug Deliv. Rev. 27:161–170 (1997).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutics and Pharmacodynamics (M/C865), College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, Chicago, Illinois, 60612

    Win L. Chiou

  2. Department of Pharmaceutics and Pharmacodynamics (M/C865), College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, Chicago, Illinois, 60612

    Sang M. Chung & Ta C. Wu

Authors
  1. Win L. Chiou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sang M. Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ta C. Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chiou, W.L., Chung, S.M. & Wu, T.C. Potential Role of P-Glycoprotein in Affecting Hepatic Metabolism of Drugs. Pharm Res 17, 903–905 (2000). https://doi.org/10.1023/A:1007570517183

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1007570517183

Search

Navigation